KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EPS (Weighted Average and Diluted) (2016 - 2025)

Neogenomics (NEO) has disclosed EPS (Weighted Average and Diluted) for 15 consecutive years, with -$0.07 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 41.67% year-over-year to -$0.07, compared with a TTM value of -$0.84 through Dec 2025, down 35.48%, and an annual FY2025 reading of -$0.84, down 35.48% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.07 for Q4 2025 at Neogenomics, up from -$0.21 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.59 in Q2 2021 and bottomed at -$0.4 in Q1 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.17, with a median of -$0.19 recorded in 2021.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 1083.33% in 2021, while the deepest fall reached 525.0% in 2021.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.35 in 2021, then surged by 48.57% to -$0.18 in 2022, then surged by 38.89% to -$0.11 in 2023, then decreased by 9.09% to -$0.12 in 2024, then soared by 41.67% to -$0.07 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for NEO at -$0.07 in Q4 2025, -$0.21 in Q3 2025, and -$0.36 in Q2 2025.